semaglutide deadline Compounded Semaglutide: FDA 2026 Rule Update As new versions of GLP-1
Description
The FDA-approved brand products (Wegovy, Zepbound) are considered first-line for obesity
doi: 10.1210/endo.139.9.6202
It is to support the body while patients build better routines
Patients discontinuing GLP-1 medications should monitor for signs of gallbladder problems (severe abdominal pain, especially after meals), pancreatitis (persistent severe abdominal pain, sometimes with vomiting), or significant hyperglycemia
Shed is one of many telehealth programs in the GLP-1 / weight management space
JUST MOVED DOWN FROM DELAWARE AND NEEDED TO FIND A NEW PRIMARY
